According to SIGA Technologies's latest financial reports the company has $0.15 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.15 B | 51.98% |
2022-12-31 | $98.79 M | -4.22% |
2021-12-31 | $0.10 B | -12.51% |
2020-12-31 | $0.11 B | 80.68% |
2019-12-31 | $65.24 M | -35.17% |
2018-12-31 | $0.10 B | 406.87% |
2017-12-31 | $19.85 M | -30.81% |
2016-12-31 | $28.7 M | -74.54% |
2015-12-31 | $0.11 B | 13.03% |
2014-12-31 | $99.71 M | 9.2% |
2013-12-31 | $91.3 M | 185.19% |
2012-12-31 | $32.01 M | -35% |
2011-12-31 | $49.25 M | 130.91% |
2010-12-31 | $21.33 M | 9.42% |
2009-12-31 | $19.49 M | 739.78% |
2008-12-31 | $2.32 M | -66.02% |
2007-12-31 | $6.83 M | -35.78% |
2006-12-31 | $10.63 M | 500.26% |
2005-12-31 | $1.77 M | -12.29% |
2004-12-31 | $2.02 M | 40.27% |
2003-12-31 | $1.44 M | -30.37% |
2002-12-31 | $2.06 M | -34.28% |
2001-12-31 | $3.14 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Sarepta Therapeutics
SRPT | $1.67 B | 1,016.41% | ๐บ๐ธ USA |
Novavax NVAX | $0.56 B | 278.63% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $0.42 B | 182.12% | ๐บ๐ธ USA |
NanoViricides NNVC | $5.24 M | -96.51% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.38 B | 159.07% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $0.11 B | -25.61% | ๐บ๐ธ USA |